New Zealand at a glance
- Population
- 5.3 million 2025
- Life expectancy at birth
- 82.0 years, 2024
- People aged 65 and over
- 17.6 % of people, 2025
- Health spending per person
- 5,022 US$ per person, 2024
- Doctors
- 3.61 per 1,000 people, 2022
Updated
Reviewed by Chandani Patel
New Zealand Microbiome Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Product, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$108.4 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $8.8 Mn | — | — |
| 2025 (base) | $11.5 Mn | +$2.6 Mn | — |
| 2026 (forecast) | $14.9 Mn | +$3.4 Mn | +29.8% |
| 2027 (forecast) | $19.3 Mn | +$4.4 Mn | +68.5% |
| 2028 (forecast) | $25.1 Mn | +$5.8 Mn | +118.7% |
| 2029 (forecast) | $32.5 Mn | +$7.5 Mn | +183.9% |
| 2030 (forecast) | $42.2 Mn | +$9.7 Mn | +268.4% |
| 2031 (forecast) | $54.8 Mn | +$12.6 Mn | +378.2% |
| 2032 (forecast) | $71.1 Mn | +$16.3 Mn | +520.8% |
| 2033 (forecast) | $92.3 Mn | +$21.2 Mn | +705.7% |
| 2034 (forecast) | $119.8 Mn | +$27.5 Mn | +945.9% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $11.5 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $119.8 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 29.8% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Product, indication and end user (see all) |
| Key players | Seres Therapeutics, Ferring Pharmaceuticals, Vedanta Biosciences, MaaT Pharma, Nestle (see all) |
| Regulator in New Zealand | MedsafeSource: Medsafe. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Microbiome therapeutics use live bacteria or their products as medicines, for infections, bowel disease and other conditions.
Key segments of the microbiome Therapeutics market include product (Fecal Microbiota Products, Live Biotherapeutics and Microbiome Modulators) and indication (C. difficile, IBD and Oncology).
Rising rates of gut and liver disease linked to diet, obesity and alcohol, more screening and new treatments are driving the microbiome Therapeutics market.
Microbiome-based treatments, earlier testing and digital gut-health programmes give the microbiome Therapeutics market room to grow.
Late diagnosis, stigma, limited specialist access and high prices of new medicines hold back the microbiome Therapeutics market.
The microbiome Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medsafe, part of the Ministry of Health, approves medicines before they can be sold.[1] Pharmac decides which medicines and medical devices the public health system pays for.[2]
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for microbiome Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in New Zealand.
What doctors and scientists are doing in Microbiome Therapeutics right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 20 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.
From our blog
New Zealand · 1 shared keyword
New Zealand · 1 shared keyword
New Zealand · 1 shared keyword
New Zealand · 1 shared keyword
New Zealand · 1 shared keyword
New Zealand · 1 shared keyword
OTC & Nutraceuticals · New Zealand
Medical Devices · New Zealand
Healthcare Services · New Zealand
Healthcare Services · New Zealand
Medical Devices · New Zealand
Healthcare Services · New Zealand